C4 Therapeutics Appoints New Chief Medical Officer

TL;DR

C4 Therapeutics just hired a new CMO, Adam Schlegel, from Verastem Oncology. Big move for their drug pipeline.

AI Summary

On June 7, 2024, C4 Therapeutics, Inc. announced the appointment of Dr. Adam R. Schlegel as Chief Medical Officer. Dr. Schlegel previously served as Senior Vice President, Clinical Development at Verastem Oncology, where he played a key role in advancing their oncology pipeline. His appointment is effective immediately.

Why It Matters

The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's strategic direction and the progression of its drug development pipeline.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can signal shifts in strategy or pipeline focus, introducing a degree of uncertainty.

Key Players & Entities

• C4 Therapeutics, Inc. (company) — Registrant
• Adam R. Schlegel (person) — Newly appointed Chief Medical Officer
• Verastem Oncology (company) — Previous employer of Dr. Schlegel
• June 7, 2024 (date) — Effective date of appointment
• June 10, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo

Filing Documents

• cccc-20240610.htm (8-K) — 33KB
• cccc-20240610xexx991.htm (EX-99.1) — 11KB
• c4tlogo1a.jpg (GRAPHIC) — 9KB
• 0001628280-24-027399.txt ( ) — 187KB
• cccc-20240610.xsd (EX-101.SCH) — 2KB
• cccc-20240610_lab.xml (EX-101.LAB) — 22KB
• cccc-20240610_pre.xml (EX-101.PRE) — 13KB
• cccc-20240610_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 10, 2024 , the Company issued a press release announcing Mr. Cooper's appointment to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Press release issued June 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: June 10, 2024 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR